首页> 外文OA文献 >Evaluation of differential disaccharide excretion in urine for non-invasive investigation of altered intestinal disaccharidase activity caused by alpha-glucosidase inhibition, primary hypolactasia, and coeliac disease.
【2h】

Evaluation of differential disaccharide excretion in urine for non-invasive investigation of altered intestinal disaccharidase activity caused by alpha-glucosidase inhibition, primary hypolactasia, and coeliac disease.

机译:评估尿液中差异性二糖排泄,用于非侵入性研究由α-葡萄糖苷酶抑制,原发性泌乳不足和乳糜泻引起的肠道二糖酶活性改变。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND/AIM: The reliability of a quantitative method for the non-invasive assessment of intestinal disaccharide hydrolysis was assessed. METHODS: Differential excretion of intact disaccharide, expressed as ratios of lactulose to appropriate hydrolysable disaccharides in urine collected following combined ingestion, has been investigated in healthy volunteers with drug induced alpha-glucosidase inhibition, in subjects with primary hypolactasia, and patients with coeliac disease. RESULTS: Oral administration of the alpha-glucosidase inhibitor 'Acarbose' (BAY g 5421, 200 mg) together with sucrose and lactulose increased the urinary sucrose/lactulose excretion ratios (% dose/10 h) fivefold. The effect was quantitatively reproducible, a higher dose of 'Acarbose' (500 mg) increasing the excretion ratio to about 1.0 indicating complete inhibition of intestinal sucrase activity. The suitability of the method for measuring differences in dose/response and duration of action was assessed by comparing three different alpha-glucosidase inhibitors (BAY g 5421, BAY m 1099, and BAY o 1248) and found to be satisfactory. Subjects with primary adult hypolactasia had urine lactose/lactulose excretion ratios raised to values indicating reduced rather than complete absence of lactase activity whereas sucrose/lactulose ratios were not significantly affected. 'Whole' intestinal disaccharidase activity assessed by this method demonstrated impairment of lactase, sucrase, and isomaltase in eight, one, and seven, respectively, of 20 patients with coeliac disease. By contrast in vitro assay of jejunal biopsy tissue indicated pan-disaccharidase deficiency in all but five of these patients. This shows the importance of distinguishing between 'local' and 'whole' intestinal performance. CONCLUSIONS: Differential urinary excretion of ingested disaccharides provides a reliable, quantitative, and non-invasive technique for assessing profiles of intestinal disaccharidase activity.
机译:背景/目的:评估定量方法的无创性评估肠道二糖水解的可靠性。方法:已在健康的具有药物诱导的α-葡萄糖苷酶抑制作用的志愿者,原发性泌乳减少症患者和乳糜泻患者中研究了完整二糖的差异排泄,表示为联合摄入后收集的尿液中乳果糖与适当的可水解二糖之比。结果:口服α-葡萄糖苷酶抑制剂“阿卡波糖”(BAY g 5421,200 mg)以及蔗糖和乳果糖可将尿中蔗糖/乳果糖的排泄率(%剂量/ 10 h)提高五倍。该作用在定量上是可重现的,较高剂量的“阿卡波糖”(500毫克)将排泄率提高至约1.0,表明完全抑制了肠蔗糖酶的活性。通过比较三种不同的α-葡萄糖苷酶抑制剂(BAY g 5421,BAY m 1099和BAY o 1248)评估了该方法测量剂量/反应和作用持续时间差异的适用性,结果令人满意。患有原发性成人泌乳不足的受试者的尿乳糖/乳果糖排泄比率提高到表明乳糖酶活性降低而不是完全缺乏的数值,而蔗糖/乳果糖比率未受到明显影响。通过这种方法评估的“整个”肠道二糖酶活性表明,在20例腹腔疾病患者中,乳糖酶,蔗糖酶和异麦芽糖酶分别受损。相比之下,空肠活检组织的体外分析表明,除五名患者外,其余患者均存在泛二糖苷酶缺乏症。这表明区分“局部”和“整个”肠道表现的重要性。结论:摄入的二糖的尿液差异排泄提供了一种可靠,定量和非侵入性的技术来评估肠道二糖酶活性的概况。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号